122 related articles for article (PubMed ID: 37588103)
1. Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka.
Abeysinghe P; Morawaka L; Gunasekara S; Suresh S; Jayathilake P; Udara P; Siriwardena P; Milliken S; Moore J; Ma D
Blood Cell Ther; 2019 Nov; 2(4):50-53. PubMed ID: 37588103
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autologous transplant with non-cryopreserved peripheral blood stem cells in myeloma and lymphoma in Algeria. 10 years' experience.
Bekadja MA; Entasoltan B; Amani K; Ouldjeriouat H; Osmani S; Bouchama S; Charef L; Arabi A; Brahimi M; Bouhass AR; Yafour N
Tunis Med; 2022 Novembre; 100(11):762-768. PubMed ID: 37551517
[TBL] [Abstract][Full Text] [Related]
3. A Deeper Depth of Response After Salvage Therapy Improves Outcomes of Autologous Stem Cell Transplantation in Relapsed Lymphoma and the Feasibility of Non-controlled Rate Freezing of Peripheral Blood Stem Cells.
Rab SU; Ali M; Mahar UR; Ahsan B; Ahmad U; Tariq Mahmood M; Siddiqui N; Bokhari SW
Cureus; 2024 Mar; 16(3):e56851. PubMed ID: 38659569
[TBL] [Abstract][Full Text] [Related]
4. Lomustine, cytarabine, cyclophosphamide, etoposide - An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors.
Gupta A; Gokarn A; Rajamanickam D; Punatar S; Thippeswamy R; Mathew L; Bagal B; Kannan S; Khattry N
J Cancer Res Ther; 2018; 14(5):926-933. PubMed ID: 30197327
[TBL] [Abstract][Full Text] [Related]
5. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
6. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.
Colita A; Colita A; Bumbea H; Croitoru A; Orban C; Lipan LE; Craciun OG; Soare D; Ghimici C; Manolache R; Gelatu I; Vladareanu AM; Pasca S; Teodorescu P; Dima D; Lupu A; Coriu D; Tomuleasa C; Tanase A
Front Oncol; 2019; 9():892. PubMed ID: 31552193
[TBL] [Abstract][Full Text] [Related]
7. Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.
Ali N; Adil SN; Shaikh MU
Stem Cells Transl Med; 2015 Aug; 4(8):873-7. PubMed ID: 26032748
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
9. Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation.
Makhani SS; Oza SP; Reich-Slotky R; Munshi PN; Biran N; Donato ML; Siegel DS; Vesole DH; Naam S; Rowley SD
Transplant Cell Ther; 2022 Jun; 28(6):306.e1-306.e7. PubMed ID: 35248777
[TBL] [Abstract][Full Text] [Related]
10. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
[TBL] [Abstract][Full Text] [Related]
11. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
[TBL] [Abstract][Full Text] [Related]
12. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[TBL] [Abstract][Full Text] [Related]
14. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G
Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427
[TBL] [Abstract][Full Text] [Related]
15.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
16. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of early infections and predictors of mortality after autologous hematopoietic stem-cell transplantation among multiple myeloma, Hodgkin, and non-Hodgkin lymphoma: the first experience from Palestine.
Amer R; Salameh H; Mosleh S; Abu-Taha A; Hamayel H; Enaya A; Adas A; Khursani A; Wild-Ali M; Mousa T; Battat M; Daifallah A; Koni A; Shawahna R
BMC Infect Dis; 2022 Sep; 22(1):725. PubMed ID: 36071381
[TBL] [Abstract][Full Text] [Related]
18. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
[TBL] [Abstract][Full Text] [Related]
19. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
20. Pattern of autologous stem cell transplants at a tertiary care government hospital, with emphasis on transplant outcomes with pre-harvest CD34+ level.
Dolai TK; De R; Sen A; Baul SN; Mitra S; Bhattacharya S; Mondal I; Mukhopadhyay K; Chattopadhyay A; Dutta S; Mandal PK
Blood Cell Ther; 2022 Feb; 5(1):16-26. PubMed ID: 36714265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
